• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

    11/15/21 8:00:00 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INMB alert in real time by email

    DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company's board of directors.

    "As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and guidance on many important issues in corporate development and strategy," stated Dr. Charles Nicolette, chief executive officer. "In his new role as chairman, his depth of experience in both biotechnology and fundraising will provide new levels of insight and guidance as we seek to advance our novel pipeline of cell-based immunotherapies directed at severe diseases including acute lymphoblastic leukemia and advanced renal cell carcinoma. We are also grateful to Dr. Byung Geon Rhee for his service as chair of our board during a formative period in the growth of CoImmune."

    Dr. Baracchini has extensive experience in structuring and negotiating research and development partnerships, mergers and acquisitions, and licensing agreements and has raised a considerable amount of money in private and public capital markets. He has personally negotiated more than 80 business transactions with multinational pharmaceutical firms, biotechnology companies, and prominent universities. He is currently a member of the board of directors at INmune Bio (NASDAQ:INMB) and 4D Pharma (AIM: DDDD) (NASDAQ:LBPS). From 2020-2021 he was chief business officer at Imago Biosciences and from 2010 to 2018 he was chief business officer at Xencor Inc. He has also held leadership roles in business development and corporate strategy at Metabasis, Elitra Pharmaceuticals, Warner-Lambert, Agouron Pharmaceuticals and Ionis Pharmaceuticals. He earned his BS in microbiology at University of Notre Dame, a PhD in molecular and cell biology at University of Texas, and his MBA at University of California, Irvine.

    "The Co-Immune CAR-CIK platform shows strong potential to deliver a new generation of immune-oncology therapies that offer significant advantages over earlier-generation CAR-T therapies," said Dr. Baracchini. "I look forward to continuing to work with the outstanding board and management team at CoImmune as we plan for many pivotal business and clinical development milestones in the months and years ahead."

    About CoImmune, Inc.

    CoImmune is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-T therapy that promises enhanced efficacy with greatly reduced toxicity. Our autologous RNA-loaded dendritic cell technology for solid tumors uses amplified total tumor mRNA to program highly engineered dendritic cells to generate immune responses against neoantigens without the need to identify them.

    For more information visit www.coimmune.com

    Investor Contact:

    Lori Harrelson

    Chief Financial Officer

    CoImmune, Inc.

    [email protected]



    Media Contact:

    Adam Daley

    Berry & Company Public Relations

    [email protected]

    212.253.8881

     



    Primary Logo

    Get the next $INMB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INMB

    DatePrice TargetRatingAnalyst
    1/28/2025$23.00Buy
    Rodman & Renshaw
    10/21/2024$20.00Buy
    Alliance Global Partners
    9/27/2024$18.00Outperform
    Raymond James
    8/22/2024$22.00Sector Outperform
    Scotiabank
    6/1/2023$16.00Outperform
    Robert W. Baird
    5/24/2022$14.00 → $7.00Buy → Neutral
    B. Riley Securities
    1/24/2022$32.00 → $20.00Buy
    B. Riley Securities
    7/7/2021$32.00 → $42.00Buy
    Maxim Group
    More analyst ratings

    $INMB
    SEC Filings

    See more
    • SEC Form S-8 filed by INmune Bio Inc.

      S-8 - Inmune Bio, Inc. (0001711754) (Filer)

      6/13/25 7:45:02 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by INmune Bio Inc.

      S-8 - Inmune Bio, Inc. (0001711754) (Filer)

      6/13/25 7:45:20 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Inmune Bio, Inc. (0001711754) (Filer)

      6/10/25 4:00:16 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care